Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Bristol-Myers Squibb Co. (BMY) PT Lowered to $47 at BMO Capital; See Much Uncertainty and Increased Risk
January 23, 2017 1:46 PM ESTBMO Capital analyst Alex Arfaei lowered his price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $47.00 (from $53.00) while maintaining a Market Perform rating. The firm still sees much uncertainty and Increased execution risk and thinks a takeout/merger is less likely.
Arfaei commented,... More
Cowen Downgrades Bristol-Myers Squibb Co. (BMY) to Market Perform
January 20, 2017 7:44 AM ESTCowen downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $55.49 yesterday.
... More